Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome). (Q34302354)

1 August 2017

Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome). (English)

1 reference

1 August 2017

1 reference

1 reference

1

Greg L Plosker

1 reference

1 August 2017

1 November 2012

1 reference

1 August 2017

1 reference

1 August 2017

26

1 reference

1 August 2017

11

1 reference

1 August 2017

993-1001

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-012-0004-3

1 August 2017

0 references

cites work

Dravet syndrome: inroads into understanding epileptic encephalopathies.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Cognitive and behavioral characteristics of children with Dravet syndrome: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

21 January 2018

Dravet syndrome history

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Epidemiology of Severe Myoclonic Epilepsy of Infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Mortality in Dravet syndrome: search for risk factors in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Current therapeutic procedures in Dravet syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Optimizing the indication of vigabatrin in children with refractory epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome)--a nationwide questionnaire survey in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Interactions between modulators of the GABA(A) receptor: Stiripentol and benzodiazepines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

The effects of stiripentol on GABA(A) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Michaelis-Menten kinetics of stiripentol in normal humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Stereoselective pharmacokinetics of stiripentol: an explanation for the development of tolerance to anticonvulsant effect.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Comparative anticonvulsant potency and pharmacokinetics of (+)-and (-)-enantiomers of stiripentol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Stiripentol in atypical absence seizures in children: an open trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Stiripentol: efficacy and tolerability in children with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Stiripentol open study in Japanese patients with Dravet syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

The pharmacologic treatment of Dravet syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-012-0004-3

Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study

21 January 2018

1 reference

12 December 2020

Stiripentol: an example of antiepileptic drug development in childhood epilepsies.

1 reference

12 December 2020

Stiripentol kinetics in epilepsy: nonlinearity and interactions

1 reference

12 December 2020

Efficacy of stiripentol in hyperthermia-induced seizures in a mouse model of Dravet syndrome

1 reference

12 December 2020

An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy

1 reference

12 December 2020

A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study

1 reference

12 December 2020

Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants

1 reference

12 December 2020

Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity

1 reference

12 December 2020

Topiramate in the treatment of severe myoclonic epilepsy in infancy

1 reference

12 December 2020

Topiramate in the treatment of highly refractory patients with Dravet syndrome

1 reference

12 December 2020

The metabolic fate of stiripentol in man.

1 reference

12 December 2020

Long-term efficacy and tolerance of stiripentaol in severe myoclonic epilepsy of infancy (Dravet's syndrome)

1 reference

12 December 2020

Lamotrigine and Seizure Aggravation in Severe Myoclonic Epilepsy

1 reference

12 December 2020

10.1007/S40263-012-0004-3

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

23018548